Sign In
Buy CCCC
$3.48
-0.180 (-4.92%)
At Close: Jul 31, 2026
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 03'rd Jan 2023
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science t
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates
09:48am, Thursday, 03'rd Nov 2022
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 0% and 30.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022
07:00am, Monday, 26'th Sep 2022
WATERTOWN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science
C4 Therapeutics: Poor Data Destroyed Preclinical Promise
08:50am, Wednesday, 04'th May 2022
CCCC showed a lot of preclinical promise for its protein degrader platform. However, first clinical data presented at AACR has destroyed the stock.
Where C4 Therapeutics Stands With Analysts
03:02pm, Thursday, 28'th Apr 2022 Benzinga
Within the last quarter, C4 Therapeutics (NASDAQ:CCCC) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
2
1
1
0
Last
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022
02:09pm, Thursday, 28'th Apr 2022 Benzinga
Upgrades
According to Johnson Rice, the prior rating for RPC Inc (NYSE:RES) was changed from Hold to Accumulate. In the first quarter, RPC showed an EPS of $0.07, compared to $0.05 from the year-ago
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease
Aeglea BioTherapeutics Inc (NAS
Why C4 Therapeutics Stock Is Plunging Today
03:07pm, Friday, 08'th Apr 2022
C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical trial of CFT7455. Cohort A,
C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
02:19pm, Friday, 08'th Apr 2022
C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL). The data will be presented
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
08:05pm, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.
– Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and Member of Organization, Leadership and C
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
03:02pm, Thursday, 10'th Mar 2022 Benzinga
Upgrades
For Alpha Metallurgical Resources Inc (NYSE:AMR), B. Riley Securities upgraded the previous rating of Neutral to Buy. For the fourth quarter, Alpha Metallurgical had an EPS of $13.30, compar
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
04:30pm, Tuesday, 08'th Mar 2022
- Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation –
C4 Therapeutics GAAP EPS of -$1.82 beats by $0.27, revenue of $45.78M beats by $12.7M
12:44pm, Thursday, 24'th Feb 2022 Seeking Alpha
C4 Therapeutics press release (CCCC): FY GAAP EPS of -$1.82 beats by $0.27.Revenue of $45.78M (+37.9% Y/Y) beats by $12.7M.
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
12:00pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting –
3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch
12:00pm, Wednesday, 16'th Feb 2022 The Motley Fool
Is it time to buy a basket of biotech stocks?
